Long-term efficacy and safety of ritonavir/indinavir at 400/400 mg twice a day in combination with two nucleoside reverse transcriptase inhibitors as first line antiretroviral therapy

HIV Medicine

Volumn 3, Issue 1, 2002, Pages 37-43

  Lichterfeld, M ^a   Nischalke, H D ^a   Bergmann, F ^b   Wiesel, W ^c   Rieke, A ^d   Theisen, A ^e   Fatkenheuer G ^f   Oette, M ^e   Carls, H ^g   Fenske, S ^h   Nadler, M ⁱ   Knechten, H ^j   Wasmuth, J C ^a   Rockstroh, J K ^k  

^a UNIVERSITY OF BONN   (Germany)

^b Virchow Medical Centre   (Germany)

^c Private Dental Office   (Germany)

^d Hospital Kemperhof   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f UNIVERSITY OF COLOGNE   (Germany)

^g Hospital Kamilianer   (Germany)

^h Private Office   (Germany)

ⁱ Private Office Jessen   (Germany)

^j Praxiszentrum   (Germany)

^k NONE

more..

Author keywords

Efficacy; Indinavir; Ritonavir; Tolerability

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CHOLESTEROL; DIDANOSINE; INDINAVIR; LAMIVUDINE; LIPID; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TRIACYLGLYCEROL; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BONE NECROSIS; CLINICAL OBSERVATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPODYSTROPHY; LONG TERM CARE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; THROMBOCYTOPENIA; VIRUS INHIBITION; VIRUS LOAD;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; RNA, VIRAL; VIRAL LOAD;

EID: 0036188251     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-2662.2001.00091.x     Document Type: Article

References (24)

1. Combination therapy containing RTV plus saquinavir has superior short-term antiretroviral efficacy: A randomized trial
2. Dual protease inhibitor therapy in HIV-infected patients: Pharmacologic rationale and clinical benefits
3. HIV-protease inhibitors
4. Pharmacokinetic interaction between RTV and IDV in healthy volunteers
5. Multiple-dose pharmacokinetics (PK) and tolerability of IDV/RTV combinations in healthy volunteers
6. Enhanced penetration of IDV in cerebrospinal fluid and semen after the addition of low-dose RTV
7. IDV can be given with regular meals when taken with RTV
8. Efficacy and safety of twice daily first-line RTV/IDV plus double nucleoside combination therapy in HIV-infected individuals
9. Final analysis of RTV (RTV) intensification in IDV (IDV) recipients with detectable HIV RNA levels
10. RTV intensification in IDV recipients with detectable HIV RNA viral levels
11. Virologic and immunologic response to combination protease inhibitor therapy with RTV and IDV in antiretroviral naive HIV patients
12. Combination therapy with IDV and RTV in antiretroviral-experienced patients
13. The Danish protease inhibitor study: A randomized study comparing the virological efficacy of 3 protease inhibitor-containing regimens for the treatment of human immunodeficiency virus type 1 infection
14. A retrospective, cohort-based survey of patients using twice-daily IDV + RTV combinations: Pharmacokinetics, safety, and efficacy
15. Resistance to human immunodeficiency virus type 1 protease inhibitors
16. RTV-saquinavir in protease inhibitor naive patients after 72 weeks
17. Lipid profile in patients on RTV/IDV salvage regimens
18. Changes in renal function associated with IDV
19. A randomized study comparing IDV (800mg tid) vs switching to IDV/RTV (800/100mg bid) in HIV patients having achieved viral suppression with IDV plus 2 nucleoside analogues: The BID Efficacy and Safety Trial (BEST)
20. BID first-line RTV/IDV 24 weeks results: German Multicenter Study
21. Alterations in serum levels of lipids and lipoproteins with IDV therapy for human immunodeficiency virus-infected patients
22. Is treatment with RTV a risk factor for myocardial infarction in HIV-infected patients?
23. Marked hypertriglyceridaemia associated with RTV therapy